Drug General Information (ID: DDIWAQ5OH9)
Drug Name			Methyldopa		Drug Info		Lithium carbonate		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antihypertensive Agents				Antimanic Agents
Structure

Mechanism of Methyldopa-Lithium carbonate Interaction (Severity Level: Moderate)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Methyldopa				Lithium carbonate
Mechanism		Increase the toxic effects of lithium carbonate				Lithium carbonate
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Methyldopa and Lithium carbonate

Recommended Action
Management		Monitoring for clinical and laboratory evidence of lithium toxicity is recommended. Patients should be advised to notify their physician if they experience symptoms of possible lithium toxicity such as drowsiness, dizziness, confusion, ataxia, vomiting, diarrhea, thirst, blurry vision, tinnitus, tremor.

References
1	O'Regan JB "Adverse interaction of lithium carbonate and methyldopa." Can Med Assoc J 115 (1976): 385-6
2	Yassa R "Lithium-methyldopa interaction." Can Med Assoc J 134 (1986): 141-2
3	Byrd GJ "Methyldopa and lithium carbonate: suspected interaction." JAMA 233 (1975): 320